News >

Vismodegib, First Hedgehog Inhibitor, Approved for BCC Patients

Ben Leach
Published: Monday, Jan 30, 2012

Vismodegib molecule

The FDA approves vismodegib to treat BCC

The FDA has approved vismodegib for the treatment of patients with basal cell carcinoma (BCC), marking the first cancer therapeutic targeting the Hedgehog pathway to gain authorization.

Erivedge will be available in the United States within 2 weeks. Roche is pursuing marketing authorization in the European Union and patients there may be able to obtain the drug through a clinical trial.
Image courtesy of BioOncology.com

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x